The reprise is from when many of us unfortunately learned the name "Martin Shkreli" from the first time.

The CEO of Mylan, makers of the EpiPen, announced that the cost of the life-saving devices would skyrocket to $600. There was an uproar, but that didn't affect the price. In fact, the company announced a generic brand for half the price. Why? Why indeed.